EIKN on Nasdaq

Eikon Therapeutics, Inc.

American biological products company based in Hayward, incorporated in Delaware. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

TickerEIKN on Nasdaq¹
IndustryBiological Products, (No Diagnostic Substances)¹
HeadquartersMillbrae, California¹
Incorporated inDE²
Business address230 Harriet Tubman Way, Millbrae, Ca 94030²
Filer category, Emerging growth company²
Legal formCorporation

See how the biggest companies compare on our leaderboards

Leadership

Who has led Eikon Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief financial officer

Alfred Lloyd Bowie Jr.2026–now

Chief operating officer

Michael A. Klobuchar2026–now

Chief financial officerAlfred Lloyd Bowie Jr. Feb 4, 2026 to now³
Chief operating officerMichael A. Klobuchar Feb 4, 2026 to now⁴

Board members and other officers (9)

OfficerBenjamin Bruno Thorner Feb 4, 2026 to now⁵
OfficerRoger M. Perlmutter Feb 4, 2026 to now⁶
Chief Medical OfficerRoy D. Baynes Feb 4, 2026 to now⁷
Board memberDavid W. Meline Feb 4, 2026 to now⁸
Board memberKenneth Frazier Feb 4, 2026 to now⁹
Board memberLeon Chen Feb 4, 2026 to now¹⁰
Board memberRobert Luther Huffines Feb 4, 2026 to now¹¹
Board memberRoger M. Perlmutter Feb 4, 2026 to now⁶
Board memberMa. Fatima Francisco Jun 15, 2026 to now¹²

Named in SEC Form D filings

People the company listed in its private-offering notices.

Executive OfficerAshish M. Kheterpal named Jun 1, 2023¹³
Executive OfficerBarbara M. Howes named Jun 1, 2023¹³
Executive OfficerDan M. Anderson named Jun 1, 2023¹³
Executive OfficerRoy M. Banes named Jun 1, 2023¹³
Executive OfficerRuss M. Berman named Jun 1, 2023¹³
DirectorDror M. Berman named Jan 6, 2022 to Feb 28, 2025¹⁴
DirectorJames M. Tananbaum named Jan 6, 2022 to Feb 28, 2025¹⁴
DirectorJoshua M. Wolfe named Feb 28, 2025¹⁴
DirectorRobbie M. Huffines named Feb 28, 2025¹⁴
DirectorRobin M. Washington named Jun 1, 2023 to Feb 28, 2025¹⁴
DirectorJosh M. Wolfe named Jun 1, 2023¹³
DirectorAdam M. Goulburn named Jan 6, 2022¹⁵

Filings

64 filings to the SEC since October 2021: 1 annual reports, 2 quarterly reports, 8 major events, 28 insider forms, 10 large holders, 3 private raises, 12 other. The latest 20:

Oct 7, 2026SCHEDULE 13G/A EDGAR
Oct 2, 2026SCHEDULE 13G/A EDGAR
Sep 8, 20264 EDGAR
Aug 14, 20268-K EDGAR
Aug 13, 202610-Q EDGAR
Aug 13, 20268-K EDGAR
Aug 6, 2026SCHEDULE 13G/A EDGAR
Aug 3, 20268-K EDGAR
Jun 15, 20263 EDGAR
Jun 10, 20268-K EDGAR
Jun 1, 20268-K EDGAR
May 15, 2026SCHEDULE 13G EDGAR
May 13, 2026SCHEDULE 13G EDGAR
May 11, 202610-Q EDGAR
May 11, 20268-K EDGAR
May 6, 2026SCHEDULE 13G EDGAR
Apr 29, 2026SCHEDULE 13G EDGAR
Mar 30, 20268-K EDGAR
Mar 30, 202610-K EDGAR
Mar 4, 20264 EDGAR

The 64 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

6 open-market trades by officers, directors and large owners since October 2021: 6 buys and 0 sales. Grants, option exercises and gifts are left out.

Date	Who	Trade	Shares	Price	Value	Filing
Sep 3, 2026	Kutzkey Tim10% owner	Buy	89,200	$11.56	$1.0M	Form 4
Feb 6, 2026	Column Group Opportunity III, LP10% owner	Buy	2,117,760	$18.00	$38.1M	Form 4
Feb 4, 2026	FRAZIER KENNETH CDirector	Buy	111,111	$18.00	$2.0M	Form 4
Feb 4, 2026	Wolfe JoshDirector	Buy	277,776	$18.00	$5.0M	Form 4
Feb 4, 2026	Lux Ventures V, L.P.10% owner	Buy	277,776	$18.00	$5.0M	Form 4
Feb 4, 2026	Foresite Capital Opportunity Management V, LLC10% owner	Buy	55,555	$18.00	$1.0M	Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

FMR LLCSCHEDULE 13G/A, 3 filings May 6, 2026 to Oct 7, 2026¹⁶
Abu Dhabi Investment AuthoritySCHEDULE 13G/A, 2 filings Feb 18, 2026 to Oct 2, 2026¹⁷
Innovation Endeavors III LPSCHEDULE 13G, 1 filing May 15, 2026¹⁸
Roger M. PerlmutterSCHEDULE 13G, 1 filing May 13, 2026¹⁹
BlackRock Portfolio Management LLCSCHEDULE 13G, 1 filing Apr 29, 2026²⁰
Column Group IV GP, LPSCHEDULE 13D, 1 filing Feb 12, 2026²¹
Foresite Capital Fund IV, L.P.SCHEDULE 13G, 1 filing Feb 11, 2026²²

Money raised

Private offerings the company reported to the SEC on Form D.

Feb 14, 2025Raised $350.7 million in a private offering of equity Form D: $400 million offered in all Form D
May 18, 2023Raised $140.8 million in a private offering of equity Form D: $535 million offered in all Form D
Dec 3, 2021Raised $517.8 million in a private offering of equity Form D: $525 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 77. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Fmr LLC	4,993,906	$65.2M	0.0%	+1,157,076
BlackRock, Inc.	4,281,425	$55.9M	0.0%	+962,046
Foresite Capital Management IV, LLC	1,943,682	$25.4M	8.7%	No change
Merck & Co., Inc.	1,666,666	$21.7M	4.1%	No change
Foresite Capital Management V, LLC	1,318,983	$17.2M	4.8%	No change
Capital World Investors	1,175,944	$15.3M	0.0%	+32,307
Vanguard Capital Management LLC	922,707	$12.0M	0.0%	−46,724
EcoR1 Capital, LLC	732,606	$9.6M	0.5%	No change
Geode Capital Management, LLC	556,955	$7.3M	0.0%	+283,024
Baker Bros. Advisors LP	555,555	$7.2M	0.0%	No change
Alliancebernstein L.P.	641,888	$6.8M	0.0%	−380,300
Soros Capital Management LLC	484,672	$6.3M	1.1%	No change
StepStone Group LP	395,340	$5.2M	0.2%	No change
Canada Pension Plan Investment Board	379,024	$4.9M	0.0%	No change
State Street Corp	354,093	$4.6M	0.0%	+313,943
Franklin Resources Inc	350,000	$4.6M	0.0%	No change
General Catalyst Group Management, LLC	305,233	$4.0M	2.1%	No change
UBS Group AG	263,932	$3.4M	0.0%	+164,524
Parkman Healthcare Partners LLC	256,053	$3.3M	0.3%	New
Charles Schwab Investment Management Inc	182,105	$2.4M	0.0%	+51,026
Schonfeld Strategic Advisors LLC	179,775	$2.3M	0.0%	New
Northern Trust Corp	175,927	$2.3M	0.0%	+130,396
Ensign Peak Advisors, Inc	170,490	$2.2M	0.0%	−29,510
Vanguard Portfolio Management LLC	148,895	$1.9M	0.0%	+135,282
Vanguard Fiduciary Trust Co	148,410	$1.9M	0.0%	+16,456

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGAREikon Therapeutics, Inc. filings on SEC EDGAR
2
SEC EDGAREikon Therapeutics, Inc. filings on SEC EDGAR
3
SEC EDGARAlfred Lloyd Bowie Jr., Chief financial officer
4
SEC EDGARMichael A. Klobuchar, Chief operating officer
5
SEC EDGARBenjamin Bruno Thorner, Officer
6
SEC EDGARRoger M. Perlmutter, Officer
7
SEC EDGARRoy D. Baynes, Chief Medical Officer
8
SEC EDGARDavid W. Meline, Board member
9
SEC EDGARKenneth Frazier, Board member
10
SEC EDGARLeon Chen, Board member
11
SEC EDGARRobert Luther Huffines, Board member
12
SEC EDGARMa. Fatima Francisco, Board member
13
SEC EDGAREikon Therapeutics, Inc. Form D naming Ashish M. Kheterpal
14
SEC EDGAREikon Therapeutics, Inc. Form D naming Dror M. Berman
15
SEC EDGAREikon Therapeutics, Inc. Form D naming Adam M. Goulburn
16
SEC EDGARFMR LLC SCHEDULE 13G/A on Eikon Therapeutics, Inc.
17
SEC EDGARAbu Dhabi Investment Authority SCHEDULE 13G/A on Eikon Therapeutics, Inc.
18
SEC EDGARInnovation Endeavors III LP SCHEDULE 13G on Eikon Therapeutics, Inc.
19
SEC EDGARRoger M. Perlmutter SCHEDULE 13G on Eikon Therapeutics, Inc.
20
SEC EDGARBlackRock Portfolio Management LLC SCHEDULE 13G on Eikon Therapeutics, Inc.
21
SEC EDGARColumn Group IV GP, LP SCHEDULE 13D on Eikon Therapeutics, Inc.
22
SEC EDGARForesite Capital Fund IV, L.P. SCHEDULE 13G on Eikon Therapeutics, Inc.